This study will evaluate bimatoprost 0.01% (LUMIGAN® RC) in patients with elevated intraocular pressure (IOP) due to primary open angle glaucoma (POAG) or ocular hypertension (OHT) in a clinical setting.
Glaucoma, Primary Open Angle
Ocular Hypertension
Bimatoprost 0.01%
Ages Eligible for Study
Adult (18-64)Older Adult (65+)
Sexes Eligible for Study
All
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Elevated IOP due to either primary open-angle glaucoma or ocular hypertension
Determined by the treating physician to require treatment with LUMIGAN® RC